No Data
No Data
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C., July 05, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on July 1, 2024, the Compensation Committee of Chimerix's Board of Directors granted inducement awards to
Express News | Chimerix: On June 27, Got Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard From Nasdaq
Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference
DURHAM, N.C., May 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patient
Buy Rating Justified by Chimerix's Upcoming Catalysts and Strong Financials
Chimerix, Inc. (NASDAQ:CMRX) Q1 2024 Earnings Call Transcript
Strong Buy Rating for Chimerix on Robust Financials and Promising Drug Pipeline